Reaching the SUMMIT? Benefits and potential risks associated with the use of tirzepatide in heart failure with preserved ejection fraction.

Med (New York, N.Y.)20251 citationPMID: 39954669

View on PubMed DOI: 10.1016/j.medj.2024.12.004

Abstract

The SUMMIT trialshowed that the dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide improves quality of life and reduces worsening heart failure (HF) events in patients with HF with preserved ejection fraction (HFpEF) and obesity. Some concerns, however, remain.

Authors

Hellenkamp, Kristian; Sato, Ryosuke; von Haehling, Stephan